Sun Pharma Advanced Research Company Limited
Financial trend (100/100) does the heavy lifting; momentum (60/100) is the drag.
Buy zoneSun Pharma Advanced Research Company Limited earns a Strong Buy from StocksWizard, with a blended score of 88/100. At ₹209.05 it trades below our blended DCF and relative-multiples fair value of ₹418.1, about 100% upside to that estimate — we read it as undervalued by 100%. On 4.5x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 25% below its 52-week high of ₹277.57 and 92% above the low of ₹108.71. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 11 of 13 investability checks, with durability 94, valuation 83 and momentum 60 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹334.48. Low-confidence estimate — limited data.
1-year price
EOD · 2026-09-2552-week range
-24.69% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy88Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 276.9%
- Pass: Low debt (D/E < 0.5): 0.42x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 6717%
- No data: Earnings growing
- Pass: Net margin ≥ 10%: 82.7%
- Pass: Current ratio > 1.5: 2.47
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- Pass: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.18
- Fail: Piotroski ≥ 7: 4/9
Annual financials
Shareholding
- Promoter75.1%
- Institutions1.8%
- Public & other23.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (276.9%).
- Healthy profit margin (82.7%).
- Up 54% over the past year.
- Financially solid — Altman Z 5.18.
Opportunities
- Revenue growing (6717% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~100% below our estimated fair value.
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited is a clinical-stage biopharmaceutical company developing pharmaceutical products focused on oncology and immunology in India and internationally. Its pipeline includes Vodobatinib (SCO-088), a BCR-ABL inhibitor in phase 2 trials for refractory chronic myelogenous leukemia, and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor modulator.
Sun Pharma Advanced Research Company Limited — frequently asked questions
Is Sun Pharma Advanced Research Company Limited a buy, hold or sell?
StocksWizard currently rates Sun Pharma Advanced Research Company Limited (SPARC) a Strong Buy, based on a blended score of 88/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Sun Pharma Advanced Research Company Limited's fair value?
Our blended DCF and relative-valuation model estimates Sun Pharma Advanced Research Company Limited's fair value at about ₹418.1, versus a current price of ₹209.05 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is Sun Pharma Advanced Research Company Limited financially healthy?
Sun Pharma Advanced Research Company Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Sun Pharma Advanced Research Company Limited's share price performed?
Sun Pharma Advanced Research Company Limited is up 54% over the past year and down 11% over three months, and last traded at ₹209.05. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.